Summary & Overview

CPT 86711: JCV (John Cunningham Virus) Antibody Immunoassay

CPT code 86711 represents a laboratory immunoassay that detects antibodies to the John Cunningham virus (JCV) in patient serum. This serologic test is clinically important for assessing prior exposure to JCV and contributing to risk stratification in patients at risk for JCV-related neurologic complications. As an identifiable lab procedure under the CPT system, 86711 is relevant to clinicians ordering JCV testing and to laboratories reporting and billing for serologic assays nationwide.

Key payers in the national context include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the clinical context for JCV antibody testing, common settings where the test is performed (clinical and hospital laboratories), and typical service classification as a laboratory immunoassay. The publication outlines benchmarking and coverage patterns where available, highlights relevant billing considerations for laboratories, and summarizes policy and coding updates that affect reporting and reimbursement of serologic JCV testing.

The content is intended to help laboratory managers, billing professionals, and clinicians understand the procedural definition of CPT code 86711, its clinical use case, and the payer landscape that commonly applies to this laboratory service. Data not available in the input will be noted where applicable.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicare86711CPTLaboratoryImmunoassayJCVSerologyNeurologyClinical Testing

Billing Code Overview

CPT code 86711 describes an immunoassay performed by a laboratory analyst to detect antibodies to the John Cunningham virus (JCV) in a patient's serum. The test evaluates the presence of JCV-specific antibodies, which can inform clinical decisions related to progressive multifocal leukoencephalopathy risk assessment and other neurologic or immunologic evaluations.

Service type: Laboratory immunoassay (serologic antibody testing)
Typical site of service: Clinical laboratory or hospital-based laboratory

Data not available in the input for payers, associated taxonomies, ICD-10 diagnoses, and related codes.

Clinical & Coding Specifications

Clinical Context

A typical patient is a 45–65-year-old individual with multiple sclerosis (MS) or another demyelinating disorder who is being considered for or currently receiving natalizumab or another immunosuppressive therapy. Prior to initiating therapy and periodically during treatment, the clinician orders a serum immunoassay to detect antibodies against John Cunningham virus (JCV) to assess the patient’s risk of progressive multifocal leukoencephalopathy (PML). The clinical workflow: the ordering neurologist places the laboratory test for 86711 in the electronic health record with indication such as risk stratification for PML; phlebotomy collects a serum sample at an outpatient infusion center or ambulatory clinic; the specimen is sent to a hospital or reference laboratory; the lab analyst performs the immunoassay and reports a qualitative or quantitative JCV antibody result in the laboratory information system; the result is routed back to the treating neurologist who documents the finding and incorporates it into treatment planning or monitoring. Typical site of service is an outpatient laboratory, hospital laboratory, or ambulatory infusion center where blood is drawn and samples are processed by trained laboratory personnel.

Coding Specifications

Modifier	Description	When to Use
`26`	Professional component	Use when billing only the professional interpretation component if the performing lab separates technical and professional components.
`TC`	Technical component	Use when billing only the technical component (laboratory testing) without the professional interpretation.
`90`	Reference (outside) laboratory	Use when the specimen is sent to an outside reference lab and billing needs to indicate testing performed by another laboratory.
`91`	Repeat clinical diagnostic laboratory test	Use when a repeat JCV antibody test is performed on the same day to confirm prior result.
`59`	Distinct procedural service	Use when this lab test is distinct from other services on the same day and needs to be reported separately.
`76`	Repeat procedure by same physician	Use when the same lab test is repeated by the performing provider (same group) on the same day.
`77`	Repeat procedure by another physician	Use when the same test is repeated by a different lab or provider on the same day.
`53`	Discontinued procedure	Use if specimen collection or testing is started but discontinued for clinical reasons.
`QW`	CLIA waived test	Use only when the specific assay is CLIA-waived and the laboratory is billing accordingly.
`QX`	Ordering physician is also NPI-qualified lab director	Use when the ordering or performing physician meets CLIA requirements for lab director and billing rules require this modifier.
`90`	Reference (outside) laboratory	Use to indicate testing performed by an external laboratory (duplicate listed for emphasis when applicable).

Taxonomy Code	Specialty	Notes
207RG0300X	Neurology	Neurologists commonly order JCV antibody testing for MS therapy risk stratification.
207RH0000X	Neurorehabilitation	Specialists involved in long-term management of demyelinating disease may order surveillance testing.
207L00000X	Anatomic and Clinical Pathology	Pathologists and laboratory medicine specialists oversee testing methodology and interpretation.
207K00000X	Clinical Laboratory	Clinical laboratory directors and medical technologists perform and validate the assay.
2084P0800X	Infectious Disease	Infectious disease specialists may order JCV testing when evaluating immunocompromised patients.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`G35`	Multiple sclerosis	Primary indication for JCV antibody testing when considering natalizumab or other high-risk immunotherapies.
`D89.9`	Disorder involving the immune mechanism, unspecified	Represents immunodeficiency or immune dysregulation states where JCV risk assessment may be relevant.
`B20`	Human immunodeficiency virus [HIV] disease	HIV-positive patients are immunocompromised and may require JCV testing if neurologic symptoms arise.
`C80.1`	Malignant (primary) neoplasm, unspecified — metastasis to brain (use cautiously)	Patients with hematologic or solid malignancies receiving immunosuppressive therapy may need JCV surveillance when neurologic symptoms occur.
`G37.9`	Demyelinating disease of central nervous system, unspecified	Broader category for demyelinating disorders where JCV testing may be part of workup.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`36415`	Collection of venous blood by venipuncture	Performed immediately before `86711` to obtain serum specimen for JCV antibody testing.
`88360`	Immunohistochemistry (IHC) staining, each antibody (if applicable for tissue-based JCV testing)	Performed when JCV detection requires tissue-based immunostaining in biopsy specimens; not typical for serum assay but relevant in PML diagnosis workflow.
`86749`	Hepatitis C antibody, screen or confirmatory (example serologic assay category)	Example of another serologic antibody test that may be ordered concurrently in immunosuppressed patients; illustrates laboratory serology workflow.
`99000`	Handling and/or conveyance of specimen (when used per payer rules)	Used when additional specimen handling or special transport is required for `86711`.
`84999`	Unlisted chemistry procedure (when specific assay lacks direct crosswalk for payer)	Used only when the laboratory needs to report a JCV assay under an unlisted chemistry code for payer adjudication or novel methodologies.